NEW YORK, NY / ACCESSWIRE / February 17, 2016 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has initiated coverage on Immune Therapeutics, Inc. (OTC: IMUN) with a price target of $0.61.
The report is available here: IMUN Initiation Report. SeeThruEquity is an approved equity research contributor on Thomson First Call, Capital IQ, FactSet, and Zack's. The report will be available on these platforms. The firm also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street.
"Immune Therapeutics, Inc. products and therapies are designed to exploit the intrinsic power of the immune system to help improve treatment of cancer, HIV/Aids, chronic inflammatory diseases, and autoimmune diseases. The Company's technology platform includes two immunotherapies: Methionine-Enkephalin and Low Dose Naltrexone or Lodonal. Both therapies have been developed for decades at US institutions and leading immunologists. Immune Therapeutics has had many accomplishments and significant progress. In December 2014, with the spin-off of Cytocom, the Company was able to retain exclusive rights to all international patent formulations, trademarks, manufacturing, marketing, sales and distribution rights in various markets. The Company will also continue to have access to new and existing clinical data generated by Cytocom during drug development," stated Ajay Tandon, CEO of SeeThruEquity. "We are initiating coverage with a 12-month price target of $0.61 per share."
Additional highlights from the report are as follows:
Low Dose Naltrexone proving to be a success
LDN has shown significant results. The Company's team has worked rigorously and diligently in uncovering Naltrexone's therapeutic properties. Naltrexone properties, which were originally used only for individuals with opiate and alcohol dependence, now has the potential to become a primary drug used for therapeutic purposes in individuals with various forms of autoimmune disorders, cancers and HIV/AIDS. The advancements and newly discovered powers of LDN since its original date of FDA approval specifically for opiate dependence in 1984 has made substantial headway. Now, Naltrexone has the potential to seamlessly enter this large and relatively untouched market.
Noteworthy progress in cancer research
MENK is a revolutionary option of therapy for those diagnosed with various forms of cancer. MENK appears to be an innovative solution in the therapy of cancer. Both Phase 1 and Phase 2 studies have shown a promising safety profile and beneficial effects on the immune system, particularly for those undergoing chemotherapy at the same time. Moreover, another major benefit of MENK is the improvement in the quality of life.
Successful enrollment and positive outlook in Lodonal clinical trials
The Company announced a 100% enrollment rate in the Lodonal clinical trials in Nigeria. Results are expected to be released sometime during Q1 of 2016. The results of this bridging study could be the medical breakthrough needed for AIDS patients in Africa and all around the world.
Significance of agreement with KRS Global
The agreement with KRS Global is essential for the further development and future profitability of Immune Therapeutics. This is an important milestone for the development of this early stage company. This new agreement will allow the Company to raise awareness and increase the availability of Naltrexone.
Please review important disclosures at www.seethruequity.com.
About Immune Therapeutics, Inc.
A specialty pharmaceutical company engaged in the manufacturing, distribution and marketing of their therapies to combat chronic, life-threatening diseases through the activation and modulation of the body's immune system. The Company's technology platform includes two immunotherapies Methionine-Enkephalin (MENK) and Low Dose Naltrexone (LDN) or Lodonal(TM). Both therapies have been developed for decades at US institutions and leading immunologists.
For more information, please visit the Company's website at www.immunetherapeutics.com.
About SeeThruEquity
SeeThruEquity is an equity research and corporate access firm focused on companies with less than $1 billion in market capitalization. The research is not paid for and is unbiased. The company does not conduct any investment banking or commission based business. SeeThruEquity is approved to contribute its research to Thomson One Analytics (First Call), Capital IQ, FactSet, Zacks, and distribute its research to its database of opt-in investors. The company also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street.
For more information visit www.seethruequity.com.
Contact:
Ajay Tandon
SeeThruEquity
[email protected]
SOURCE: SeeThruEquity